|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
0.56/1.87
|
企業價值
1.95B
|
資產負債 |
每股賬面淨值
4.75
|
現金流量 |
現金流量率
0.09
|
損益表 |
收益
398.20M
|
每股收益
2.95
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/05/16 00:16 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome. |